Achilles therapeutics reports first quarter 2022 financial results and recent business highlights

- dosed first patient with higher-dose (process 2) cnet for advanced nsclc (chiron) and initiated enrollment of cnet + pd-1 inhibitor combination (thetis cohort b) for metastatic malignant melanoma -
ACHL Ratings Summary
ACHL Quant Ranking